Sulfur hexafluoride 8microlitres/ml powder and solvent for dispersion for injection vials
Requires a prescription from a doctor or prescriber
Chemical compound, non-toxic, climate-damaging gas
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Sulfur hexafluoride
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Sulfur hexafluoride on the MHRA register
SonoVue 8microlitres/ml powder and solvent for dispersion for injection vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 30 studies.
Reviews & meta-analyses: 5 · 2000–2025
Showing all 30 studies, sorted by most relevant.
A. Beroual, A. Haddad
Energies, 2017
The growing environmental challenge of electrical energy systems has prompted a substantial increase in renewable energy generation. Such generation systems allow for significant reduction of CO2 emissions compared with a traditional fossil fuel plant. Furthermore, several improvements in power systems network configuration and operation combined with new technologies have enabled reduction of losses and energy demand, thus contributing to reduction of CO2 emissions. Another environmental threat identified in electrical networks is the leaking of insulating sulfur hexafluoride (SF6) gas used in electrical gas insulated substations (GIS) and equipment. Because of its Global Warming Potential (GWP) of nearly 24,000 and its long life in the atmosphere (over 3000 years), SF6 gas was recognized as a greenhouse gas at the 1997 COP3; since then its use and emissions in the atmosphere have been regulated by international treaties. It is expected that as soon as an alternative insulating gas is found, SF6 use in high-voltage (HV) equipment will be banned. This paper presents an overview of the key research advances made in recent years in the quest to find eco-friendly gases to replace SF6. The review reports the main properties of candidate gases that are being investigated; in particular, natural gases (dry air, N2 or CO2) and polyfluorinated gases especially Trifluoroiodomethane (CF3I), Perfluorinated Ketones, Octafluorotetra-hydrofuran, Hydrofluoroolefin (HFOs), and Fluoronitriles are presented and their strengths and weaknesses are discussed with an emphasis on their dielectric properties (especially their dielectric strength), GWP, and boiling point with respect to the minimum operating temperature for HV power network applications.
Abstract licence: CC BY
Jin Jin, Yulan Zhao, Pintong Huang
European Radiology, 2023
- Leiomyoma
- Sulfur Hexafluoride
- Uterine Neoplasms
E. Qu, Man Zhang, Jin-xiu Ju, et al.
Journal of Ultrasound in Medicine, 2022
- Fallopian Tubes
- Infertility, Female
- Contrast Media
J. Chu, Xiaohua Wang, Dawei Wang, et al.
Carbon, 2018
Shengyao Shi, Yi Li, Zhaolun Cui, et al.
Chemical Engineering Journal, 2023
P. Simmonds, M. Rigby, A. Manning, et al.
Atmospheric Chemistry and Physics, 2020
Abstract. We report a 40-year history of SF6 atmospheric mole fractions measured at the Advanced Global Atmospheric Gases Experiment (AGAGE) monitoring sites, combined with archived air samples to determine emission estimates from 1978–2018. Previously we reported a global emission rate of 7.3 ± 0.6 Gigagrams (Gg) yr−1 in 2008 and over the past decade emissions have continued to increase by about 24 % to 9.04 ± 0.35 Gg yr−1 in 2018. We show that changing patterns in SF6 consumption from developed (Kyoto Protocol Annex-1) to developing countries (non-Annex-1) and the rapid global expansion of the electric power industry, mainly in Asia, have increased the demand for SF6-insulated switchgear, circuit breakers and transformers. The large bank of SF6 sequestered in this electrical equipment provides a substantial source of emissions from maintenance, replacement and continuous leakage. Other emissive sources of SF6 occur from the magnesium, aluminium, electronics industries and more minor industrial applications. More recently, reported emissions, including those from electrical equipment and metal industries, primarily in the Annex-1 countries, have steadily declined through substitution of alternative blanketing gases and technological improvements in less emissive equipment and more efficient industrial practices. Conversely, in the non-Annex-1 countries SF6 emissions have increased due to an expansion in the growth of the electrical power, metal and electronics industries to support their development. There is an annual difference of 2.5–5 Gg yr−1 (1990–2018) between our modelled top-down emissions and the UNFCCC reported bottom-up emissions, which we attempt to reconcile through analysis of the potential contribution of emissions from the various industrial applications which use SF6. We also investigate regional emissions in East Asia (China, S. Korea) and Western Europe and their respective contributions to the global atmospheric SF6 inventory. On an average annual basis, our estimated emissions from the whole of China are approximately 10 times greater than emissions from Western Europe. In 2018, our modelled Chinese and Western European emissions accounted for ~ 36 % and 3.1 %, respectively, of our global SF6 emissions estimate.
Abstract licence: CC BY
David Rombach, H. Wagenknecht
Synthesis, 2022
Minde An, R. Prinn, L. Western, et al.
Nature Communications, 2024
Abstract Sulfur hexafluoride (SF 6 ) is a potent greenhouse gas. Here we use long-term atmospheric observations to determine SF 6 emissions from China between 2011 and 2021, which are used to evaluate the Chinese national SF 6 emission inventory and to better understand the global SF 6 budget. SF 6 emissions in China substantially increased from 2.6 (2.3-2.7, 68% uncertainty) Gg yr −1 in 2011 to 5.1 (4.8-5.4) Gg yr −1 in 2021. The increase from China is larger than the global total emissions rise, implying that it has offset falling emissions from other countries. Emissions in the less-populated western regions of China, which have potentially not been well quantified in previous measurement-based estimates, contribute significantly to the national SF 6 emissions, likely due to substantial power generation and transmission in that area. The CO 2 -eq emissions of SF 6 in China in 2021 were 125 (117-132) million tonnes (Mt), comparable to the national total CO 2 emissions of several countries such as the Netherlands or Nigeria. The increasing SF 6 emissions offset some of the CO 2 reductions achieved through transitioning to renewable energy in the power industry, and might hinder progress towards achieving China’s goal of carbon neutrality by 2060 if no concrete control measures are implemented.
Abstract licence: CC BY
Lingling Li, Xue-bin Zou, Wei-Hong Zheng, et al.
Radiology, 2023
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Fluorocarbons
Eunjin Jo, Sanghee Yang, Dong Wook Kim, et al.
Coordination Chemistry Reviews, 2024
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
10 minutes
Mechanism
Within the blood, the acoustic impedance of Lumason microspheres is lower than t…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
0.03 mL
Half-life
10 minutes
Volume of distribution
341 L
Metabolism
88%
Elimination
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
•in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
•in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
Ultrasonography of the Liver: Sulfur hexafluoride is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions.
For ultrasonography of the liver, Sulfur hexafluoride provides dynamic patterns of differential signal intensity enhancement between focal liver lesions and liver parenchyma during the arterial, portal venous, and late phase of signal intensity enhancement of the microvasculature.
How the body processes this drug — absorption, distribution, metabolism, and elimination
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Sulfur hexafluoride
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q279055), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.